1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

Two for the price of two: Cubist fronts $1.24b for Trius, Optimer

 
• By Mandy Jackson

Why buy one antibiotic developer when you can buy two? Cubist Pharmaceuticals will spend up to $1.62 billion for Trius Therapeutics and Optimer Pharmaceuticals, whose lead drugs Cubist believes will generate $600 million to $1 billion in combined annual revenue at their peak.

Why buy one antibiotic developer when you can buy two? Cubist Pharmaceuticals will spend up to $1.62 billion for Trius Therapeutics and Optimer Pharmaceuticals, whose lead drugs Cubist believes will generate $600 million to $1 billion in combined annual revenue at their peak.

Cubist agreed to pay Trius investors $13.50 per share for a total of $707 million and offered Optimer stockholders $10.75...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

Phase III Success For AiCuris’s Herpes Simplex Treatment

 
• By Andrew McConaghie

The German company is now gearing up for a US filing for a product that overcomes drug resistance issues in herpes simplex, and which it believes could transform its business.

Valneva Secures $500m Financing Ahead Of Lyme Disease Vaccine Readout

 
• By Kevin Grogan

The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.

Enanta Plans Phase III Trial Of Zelicapavir Despite Primary Endpoint Miss

 
• By Alaric DeArment

The company announced Phase IIb results for the RSV drug that showed positive data across multiple key secondary endpoints, some of which could serve as a primary endpoint in Phase III.

Having Steadied GSK’s Ship, Walmsley To Step Down As Chief

 
• By Kevin Grogan

Chief commercial officer Luke Miels to take over in 'seamless succession'.

More from Therapy Areas

How To Score A Win With Real-World Evidence In India

 
• By Vibha Ravi

Bharat Serums showed it’s possible to score a regulatory win with real-world evidence (RWE) studies in India when it ran one leading to a label expansion for its mAb trinbelimab. As cell and gene therapies and rare disease drugs gain currency, sponsors could look at takeaways from the RhYTHM study.

Failing to Clinch Sale, Galapagos To Wind Down Cell Therapy Business

 
• By Manas Mishra

Galapagos is closing its cell therapy business after a prolonged search for buyers, leading to job cuts and site closures in the US, Netherlands, Switzerland and China.

Summit Presses Ahead With Ivonescimab Filing Despite Approval Doubts

 
• By Andrew McConaghie

Frontrunner believes it can gain a first approval in EGFR+ lung cancer, even though the FDA recently raised the bar on overall survival.